Innovotech Receives First Purchase Order for New InnovoSCEPT(TM) Veterinary Biofilm Tests
June 13 2011 - 8:00AM
Marketwired
Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of
biofilm product development, today announced that it has received
its first purchase order for InnovoSCEPT™ veterinary biofilm
susceptibility tests for launch into the Japanese veterinary
market. The Company anticipates expansion to the balance of the
worldwide veterinary market to follow quickly.
"This initial order of InnovoSCEPT™ veterinary tests provides a
new and improved method to identify effective treatments for
chronic infections in animals. The situation in the animal world
parallels what is seen in human health, where inappropriate
treatment of chronic infections results in unnecessary patient
suffering, repeated treatment failures, increased health care costs
and an increase in the potential for bacterial resistance," said
Ken Boutilier, President and CEO of Innovotech. "Our company has
developed the InnovoSCEPT™ line of five new products for
susceptibility testing in both humans and animals in less than six
months. This initial purchase order for introduction into the
Japanese market is just the start of what should become an
important revenue generator."
The InnovoSCEPT™ line of veterinary tests, based on the
technology used to develop Innovotech's bioFILM PA™ human
susceptibility test, will assist veterinarians in the selection of
the most effective antibiotic treatment of infections caused by
both gram-positive and gram-negative bacteria in both small and
large animals. As with human infections, many common
disease-causing bacteria exist in animals as biofilms, such as
those responsible for infections causing mastitis in dairy cows or
persistent skin infections in family pets. These chronic infections
are often difficult to eradicate and Innovotech's tests have a much
better chance of being successful in the identification of the best
treatment approach in comparison to current methods.
Biofilms are organized communities of microorganisms that exist
in virtually every natural environment. Biofilms can be up to 1000
times more resistant to treatment than the same organism in a
free-floating state.
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product
development, focused on providing innovative and practical
solutions to medical, agricultural and industrial problems caused
by microbial biofilms. Biofilms are responsible for a host of
diseases both in human health and agriculture due to their inherent
resistance to existing antibiotics and disinfectants. Aside from
Innovotech's products there are no antibiotics, disinfectants,
diagnostics or regulatory standards designed specifically for
biofilm-forming organisms.
Innovotech has a broad range of products that address the issue
of biofilms within a number of different industries, including
three commercial products, the MBEC Assay™, bioFILM PA™ and
InnovoSCEPT™ veterinary kits. The MBEC Assay™ is a high throughput
biofilm growth device that was recently approved as an ASTM
International standard. bioFILM PA™ is the first diagnostic kit to
assist physicians in the selection of the most effective
combination antibiotic treatment of patients with biofilm-based
chronic lung infections, while the InnovoSCEPT™ veterinary kits are
designed to determine the most effective antibiotic treatment for
infections in both large and small animals.
Innovotech also has two products in advanced stages of
development; Agress® is a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both
bacterial and fungal infections and Sani-Lux™ is a light-activated,
natural hard surface sanitizer.
Connect with us:
Website: www.innovotech.ca
Blog: www.cf-test.ca
Twitter:www.twitter.com/innovotech
Facebook:www.facebook.com/innovotech
This document may contain forward-looking statements that are
predictive in nature and subject to risks and uncertainties that
cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or
contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of
predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contacts: Innovotech Inc. Ken Boutilier President and CEO (780)
448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca
Innovotech Inc. Amanda Stadel Communications Officer (780) 448-0585
ext. 224 (780) 424-0941 (FAX) amanda.stadel@innovotech.ca
www.innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Aug 2023 to Aug 2024